what is glp-1 microdose Injections Go Micro with the Noom

You have a BMI of 27 or higher plus a weight-related comorbidity approved by Cigna, including (but not limited to) hypertension, Type 2 diabetes, obstructive sleep apnea, and CV disease

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist with rapidly growing use, has demonstrated even greater effects on glycemic control and weight loss 13,14,15

Jiang explained that SUSTAIN-China showed average blood sugar was reduced by 1.4 percent to 1.7 percent with semaglutide after 30 weeks, whereas with ecnoglutide it dropped by 1.89 percent to 1.91 percent after 32 weeks (shown in the separate study)

Less Common but Noteworthy Side Effects While most side effects from GLP-1 medications are mild and manageable, some patients may experience more serious side effects that require close monitoring

Second, clinicians should leverage digital tools responsibly

And while nutrition and movement are essential, theyre only part of a bigger picture